Gastroparesis News and Research

RSS
Gastroparesis, also called delayed gastric emptying, is a disorder in which the stomach takes too long to empty its contents. Normally, the stomach contracts to move food down into the small intestine for digestion. The vagus nerve controls the movement of food from the stomach through the digestive tract. Gastroparesis occurs when the vagus nerve is damaged and the muscles of the stomach and intestines do not work normally. Food then moves slowly or stops moving through the digestive tract.
New possibilities for relief from digestive diseases

New possibilities for relief from digestive diseases

Amylin and Lilly terminate exenatide alliance, resolve litigation

Amylin and Lilly terminate exenatide alliance, resolve litigation

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

New ways for treating diabetes

New ways for treating diabetes

Exenatide tQT clinical trial meets pre-specified primary endpoint

Exenatide tQT clinical trial meets pre-specified primary endpoint

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Prior GID diagnosis impacts health outcomes of patients with Parkinson's

Prior GID diagnosis impacts health outcomes of patients with Parkinson's

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

Amylin disappointed with U.S. District Court's ruling in BYETTA preliminary injunction

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

Eli Lilly responds to Amylin's exenatide lawsuit

Eli Lilly responds to Amylin's exenatide lawsuit

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Amylin files lawsuit against Eli Lilly for improper commercialization of exenatide

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

FDA clears Multi-Lead Trialing Cable for SCS therapy

FDA clears Multi-Lead Trialing Cable for SCS therapy

FDA issues complete response letter for BYDUREON NDA

FDA issues complete response letter for BYDUREON NDA

Preliminary Phase 2 data of TZP-102 for diabetic gastroparesis to be presented at ACG annual meeting

Preliminary Phase 2 data of TZP-102 for diabetic gastroparesis to be presented at ACG annual meeting

Tranzyme Pharma to present ulimorelin Phase 2 data at NGM Meeting

Tranzyme Pharma to present ulimorelin Phase 2 data at NGM Meeting

Medtronic launches Defeat-HF clinical trial to evaluate SCS for heart failure

Medtronic launches Defeat-HF clinical trial to evaluate SCS for heart failure

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy